Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes.

Loosen, Sven H; Kostev, Karel; Luedde, Mark; Qvartskhava, Natalia; Luedde, Tom; Roderburg, Christoph

Loosen, Sven H; Kostev, Karel; Luedde, Mark; Qvartskhava, Natalia; Luedde, Tom; Roderburg, Christoph.

Afiliação

Loosen SH; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany Sven.Loosen@med.uni-duesseldorf.de.
Kostev K; Epidemiology, IQVIA, Frankfurt, Germany.
Luedde M; Department of Internal Medicine, Christian Albrechts University of Kiel, Kiel, Germany.
Qvartskhava N; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Luedde T; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Roderburg C; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Gut ; 71(8): 1687-1688, 2022 08.

Article em En | MEDLINE | ID: mdl-34725199

Assuntos

Diabetes Mellitus Tipo 2; Inibidores da Bomba de Prótons; Diabetes Mellitus Tipo 2/tratamento farmacológico; Humanos; Inibidores da Bomba de Prótons/efeitos adversos; Medição de Risco

Palavras-chave

adverse drug reactions; diabetes mellitus; proton pump inhibition

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores da Bomba de Prótons Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Gut Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google